Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg, Fatima Amanat, Adolfo Firpo, Deena R Altman, Mark J Bailey, Mayce Mansour, Meagan McMahon, Philip Meade, Damodara Rao Mendu, Kimberly Muellers, Daniel Stadlbauer, Kimberly Stone, Shirin Strohmeier, Viviana Simon, Judith Aberg, David L Reich, Florian Krammer, Carlos Cordon-Cardo, Ania Wajnberg, Fatima Amanat, Adolfo Firpo, Deena R Altman, Mark J Bailey, Mayce Mansour, Meagan McMahon, Philip Meade, Damodara Rao Mendu, Kimberly Muellers, Daniel Stadlbauer, Kimberly Stone, Shirin Strohmeier, Viviana Simon, Judith Aberg, David L Reich, Florian Krammer, Carlos Cordon-Cardo

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Figures

Fig. 1. SARS-CoV-2 spike antibody titers in…
Fig. 1. SARS-CoV-2 spike antibody titers in 30,082 individuals.
(A) The percentage of individuals with antibody titers of 1:80 (low), 1:160 (low), 1:320 (moderate), 1:960 (high), and ≥1:2880 (high). (B) Absolute numbers of individuals testing positive and percent of individuals with titers of 1:320 over time. Testing of each sample was performed once in a Clinical Laboratory Improvement Amendments (CLIA)–certified laboratory using an assay that received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).
Fig. 2. Neutralizing activity of serum samples…
Fig. 2. Neutralizing activity of serum samples in relation to ELISA titers.
(A) A correlation analysis between ELISA titers on the x axis and neutralization titers in a microneutralization assay on the y axis. The Spearman ρ was determined. Red bars indicate the geometric mean. (B) The proportion of sera that exert any neutralizing activity in each of the ELISA titer categories. Testing was performed once, using an FDA EUA ELISA in a CLIA laboratory, or twice, following a standardized neutralization protocol.
Fig. 3. Antibody titer stability over time.
Fig. 3. Antibody titer stability over time.
(A) Titers of 121 volunteers whose blood was initially drawn ~30 days after COVID-19 symptom onset and who were then recalled for additional blood draws at ~82 days and 148 days after symptom onset. (B to F) The same data as in (A), but stratified by the initial (day 30) titer. Titers are graphed as geometric mean titers (GMT) with geometric standard error. (G) Neutralization titers of 36 individuals over time. A paired one-way analysis of variance corrected for multiple comparison was used to determine statistical significance. (H) A correlation analysis between ELISA titers on the x axis and neutralization titers in a microneutralization assay on the y axis at day 148. Red bars indicate the geometric mean. The Spearman ρ was determined. Testing was performed once, using an FDA EUA ELISA in a CLIA-certified laboratory, or twice, following a standardized neutralization protocol.

References

    1. Liu L., To K. K.-W., Chan K.-H., Wong Y.-C., Zhou R., Kwan K.-Y., Fong C. H.-Y., Chen L.-L., Choi C. Y.-K., Lu L., Tsang O. T.-Y., Leung W.-S., To W.-K., Hung I. F.-N., Yuen K.-Y., Chen Z., High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg. Microbes Infect. 9, 1664–1670 (2020). 10.1080/22221751.2020.1791738
    1. Long Q. X., Liu B.-Z., Deng H.-J., Wu G.-C., Deng K., Chen Y.-K., Liao P., Qiu J.-F., Lin Y., Cai X.-F., Wang D.-Q., Hu Y., Ren J.-H., Tang N., Xu Y.-Y., Yu L.-H., Mo Z., Gong F., Zhang X.-L., Tian W.-G., Hu L., Zhang X.-X., Xiang J.-L., Du H.-X., Liu H.-W., Lang C.-H., Luo X.-H., Wu S.-B., Cui X.-P., Zhou Z., Zhu M.-M., Wang J., Xue C.-J., Li X.-F., Wang L., Li Z.-J., Wang K., Niu C.-C., Yang Q.-J., Tang X.-J., Zhang Y., Liu X.-M., Li J.-J., Zhang D.-C., Zhang F., Liu P., Yuan J., Li Q., Hu J.-L., Chen J., Huang A.-L., Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020). 10.1038/s41591-020-0897-1
    1. Krammer F., Simon V., Serology assays to manage COVID-19. Science 368, 1060–1061 (2020). 10.1126/science.abc1227
    1. Wrapp D., Wang N., Corbett K. S., Goldsmith J. A., Hsieh C.-L., Abiona O., Graham B. S., McLellan J. S., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020). 10.1126/science.abb2507
    1. Letko M., Marzi A., Munster V., Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020). 10.1038/s41564-020-0688-y
    1. Amanat F., Krammer F., SARS-CoV-2 vaccines: Status report. Immunity 52, 583–589 (2020). 10.1016/j.immuni.2020.03.007
    1. Amanat F., Stadlbauer D., Strohmeier S., Nguyen T. H. O., Chromikova V., McMahon M., Jiang K., Arunkumar G. A., Jurczyszak D., Polanco J., Bermudez-Gonzalez M., Kleiner G., Aydillo T., Miorin L., Fierer D. S., Lugo L. A., Kojic E. M., Stoever J., Liu S. T. H., Cunningham-Rundles C., Felgner P. L., Moran T., García-Sastre A., Caplivski D., Cheng A. C., Kedzierska K., Vapalahti O., Hepojoki J. M., Simon V., Krammer F., A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020). 10.1038/s41591-020-0913-5
    1. Wajnberg A., Mansour M., Leven E., Bouvier N. M., Patel G., Firpo-Betancourt A., Mendu R., Jhang J., Arinsburg S., Gitman M., Houldsworth J., Sordillo E., Paniz-Mondolfi A., Baine I., Simon V., Aberg J., Krammer F., Reich D., Cordon-Cardo C., Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: An observational study. Lancet 1, e283–e289 (2020). 10.1016/S2666-5247(20)30120-8
    1. D. Stadlbauer, J. Tan, K. Jiang, M. Hernandez, S. Fabre, F. Amanat, C. Teo, G. A. Arunkumar, M. McMahon, J. Jhang, M. Nowak, V. Simon, E. Sordillo, H. van Bakel, F. Krammer, Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. medRxiv 2020.06.2028.20142190 [Preprint]. 29 June 2020. 10.1101/2020.06.28.20142190.10.1101/2020.06.28.20142190
    1. Stadlbauer D., Amanat F., Chromikova V., Jiang K., Strohmeier S., Arunkumar G. A., Tan J., Bhavsar D., Capuano C., Kirkpatrick E., Meade P., Brito R. N., Teo C., McMahon M., Simon V., Krammer F., SARS-CoV-2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020). 10.1002/cpmc.100
    1. Liu S. T. H., Lin H.-M., Baine I., Wajnberg A., Gumprecht J. P., Rahman F., Rodriguez D., Tandon P., Bassily-Marcus A., Bander J., Sanky C., Dupper A., Zheng A., Nguyen F. T., Amanat F., Stadlbauer D., Altman D. R., Chen B. K., Krammer F., Mendu D. R., Firpo-Betancourt A., Levin M. A., Bagiella E., Casadevall A., Cordon-Cardo C., Jhang J. S., Arinsburg S. A., Reich D. L., Aberg J. A., Bouvier N. M., Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat. Med. 10.1038/s41591-020-1088-9 (2020). 10.1038/s41591-020-1088-9
    1. Amanat F., White K. M., Miorin L., Strohmeier S., McMahon M., Meade P., Liu W.-C., Albrecht R. A., Simon V., Martinez-Sobrido L., Moran T., García-Sastre A., Krammer F., An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr. Protoc. Microbiol. 58, e108 (2020). 10.1002/cpmc.108
    1. Long Q. X., Tang X.-J., Shi Q.-L., Li Q., Deng H.-J., Yuan J., Hu J.-L., Xu W., Zhang Y., Lv F.-J., Su K., Zhang F., Gong J., Wu B., Liu X.-M., Li J.-J., Qiu J.-F., Chen J., Huang A.-L., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020). 10.1038/s41591-020-0965-6
    1. Krammer F., Weir J. P., Engelhardt O., Katz J. M., Cox R. J., Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines. Influenza Other Respir. Viruses 14, 237–243 (2020). 10.1111/irv.12706
    1. Plotkin S. A., Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055–1065 (2010). 10.1128/CVI.00131-10
    1. Van Herck K., Van Damme P., Inactivated hepatitis A vaccine-induced antibodies: Follow-up and estimates of long-term persistence. J. Med. Virol. 63, 1–7 (2001). 10.1002/1096-9071(200101)63:1<1::AID-JMV1000>;2-U
    1. Huang A. T., Garcia-Carreras B., Hitchings M. D. T., Yang B., Katzelnick L. C., Rattigan S. M., Borgert B. A., Moreno C. A., Solomon B. D., Trimmer-Smith L., Etienne V., Rodriguez-Barraquer I., Lessler J., Salje H., Burke D. S., Wesolowski A., Cummings D. A. T., A systematic review of antibody mediated immunity to coronaviruses: Kinetics, correlates of protection, and association with severity. Nat. Commun. 11, 4704 (2020). 10.1038/s41467-020-18450-4
    1. Deng W., Bao L., Liu J., Xiao C., Liu J., Xue J., Lv Q., Qi F., Gao H., Yu P., Xu Y., Qu Y., Li F., Xiang Z., Yu H., Gong S., Liu M., Wang G., Wang S., Song Z., Liu Y., Zhao W., Han Y., Zhao L., Liu X., Wei Q., Qin C., Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369, 818–823 (2020). 10.1126/science.abc5343
    1. Chandrashekar A., Liu J., Martinot A. J., McMahan K., Mercado N. B., Peter L., Tostanoski L. H., Yu J., Maliga Z., Nekorchuk M., Busman-Sahay K., Terry M., Wrijil L. M., Ducat S., Martinez D. R., Atyeo C., Fischinger S., Burke J. S., Slein M. D., Pessaint L., Van Ry A., Greenhouse J., Taylor T., Blade K., Cook A., Finneyfrock B., Brown R., Teow E., Velasco J., Zahn R., Wegmann F., Abbink P., Bondzie E. A., Dagotto G., Gebre M. S., He X., Jacob-Dolan C., Kordana N., Li Z., Lifton M. A., Mahrokhian S. H., Maxfield L. F., Nityanandam R., Nkolola J. P., Schmidt A. G., Miller A. D., Baric R. S., Alter G., Sorger P. K., Estes J. D., Andersen H., Lewis M. G., Barouch D. H., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812–817 (2020). 10.1126/science.abc4776
    1. Shi R., Shan C., Duan X., Chen Z., Liu P., Song J., Song T., Bi X., Han C., Wu L., Gao G., Hu X., Zhang Y., Tong Z., Huang W., Liu W. J., Wu G., Zhang B., Wang L., Qi J., Feng H., Wang F.-S., Wang Q., Gao G. F., Yuan Z., Yan J., A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020). 10.1038/s41586-020-2381-y
    1. Imai M., Iwatsuki-Horimoto K., Hatta M., Loeber S., Halfmann P. J., Nakajima N., Watanabe T., Ujie M., Takahashi K., Ito M., Yamada S., Fan S., Chiba S., Kuroda M., Guan L., Takada K., Armbrust T., Balogh A., Furusawa Y., Okuda M., Ueki H., Yasuhara A., Sakai-Tagawa Y., Lopes T. J. S., Kiso M., Yamayoshi S., Kinoshita N., Ohmagari N., Hattori S. I., Takeda M., Mitsuya H., Krammer F., Suzuki T., Kawaoka Y., Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. U.S.A. 117, 16587–16595 (2020). 10.1073/pnas.2009799117
    1. Yu J., Tostanoski L. H., Peter L., Mercado N. B., McMahan K., Mahrokhian S. H., Nkolola J. P., Liu J., Li Z., Chandrashekar A., Martinez D. R., Loos C., Atyeo C., Fischinger S., Burke J. S., Slein M. D., Chen Y., Zuiani A., Lelis F. J. N., Travers M., Habibi S., Pessaint L., Van Ry A., Blade K., Brown R., Cook A., Finneyfrock B., Dodson A., Teow E., Velasco J., Zahn R., Wegmann F., Bondzie E. A., Dagotto G., Gebre M. S., He X., Jacob-Dolan C., Kirilova M., Kordana N., Lin Z., Maxfield L. F., Nampanya F., Nityanandam R., Ventura J. D., Wan H., Cai Y., Chen B., Schmidt A. G., Wesemann D. R., Baric R. S., Alter G., Andersen H., Lewis M. G., Barouch D. H., DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806–811 (2020). 10.1126/science.abc6284

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する